Amgen Inc. vs Dr. Reddy's Laboratories Limited: SG&A Expense Trends

Pharma Giants' SG&A Expenses: A Decade of Divergence

__timestampAmgen Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014469900000038783000000
Thursday, January 1, 2015484600000042585000000
Friday, January 1, 2016506200000045702000000
Sunday, January 1, 2017487000000046372000000
Monday, January 1, 2018533200000046910000000
Tuesday, January 1, 2019515000000048890000000
Wednesday, January 1, 2020573000000050129000000
Friday, January 1, 2021536800000054559000000
Saturday, January 1, 2022541400000062081000000
Sunday, January 1, 20236179000000105931000000
Monday, January 1, 2024709600000077201000000
Loading chart...

In pursuit of knowledge

SG&A Expense Trends: Amgen Inc. vs Dr. Reddy's Laboratories Limited

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Amgen Inc. and Dr. Reddy's Laboratories Limited have showcased distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses have seen a steady increase, peaking at approximately $6.2 billion in 2023, marking a 31% rise from 2014. In contrast, Dr. Reddy's Laboratories experienced a more dramatic surge, with expenses skyrocketing by 173% to over $105 billion in 2023. This stark difference highlights the diverse strategic approaches of these pharmaceutical giants. While Amgen's growth appears consistent, Dr. Reddy's Laboratories' expenses reflect a more aggressive expansion strategy. Notably, data for 2024 is incomplete, indicating potential shifts in these trends. Stay tuned as we continue to monitor these financial dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025